Key result
High pericoronary fat attenuation index is linked to ~5-fold higher MACE risk.
Why the study?
Does a high computed tomography-derived pericoronary fat attenuation index (FAI) predict major adverse cardiovascular events (MACE) in patients with suspected or confirmed CAD?
Meta-Analysis (n=10,288)
Does a high computed tomography-derived pericoronary fat attenuation index (FAI) predict major adverse cardiovascular events (MACE) in patients with suspected or confirmed CAD?
Hazard Ratio: 5 (95% CI 3.3–7.58)
p-value: p=<0.001
CCTA-derived pericoronary fat attenuation index (FAI) is a strong independent predictor of MACE, highlighting its potential for improving individual cardiovascular risk stratification beyond traditional anatomical evaluation.
High FAI may enhance CCTA-based MACE risk stratification; leaves open prospective validation before routine adoption.
Background: Perivascular adipose tissue (PVAT) plays a significant role in the pathophysiology of atherosclerosis. Changes in its computed tomography (CT) attenuation reflect the inflammatory status of the vascular wall. The pericoronary fat attenuation index (FAI), derived from coronary computed tomography angiography (CCTA), is a non-invasive imaging biomarker that quantifies the CT attenuation of pericoronary fat to indirectly assess local inflammatory activity. This study aimed to evaluate the predictive value of CCTA-derived FAI for major adverse cardiovascular events (MACEs) through a meta-analysis. Methods: Two investigators systematically searched the PubMed and Web of Science databases from inception until 21 October 2025 for cohort studies assessing the association between FAI and MACE. Study quality was assessed using the Newcastle-Ottawa Scale (NOS), and the quality of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Adjusted hazard ratios (aHRs) and their 95% confidence intervals (CIs) were pooled using a random-effects model. Meta-analysis and sensitivity analyses were performed to explore sources of heterogeneity and the robustness of the results. Results: low FAI): high FAI was significantly associated with an increased risk of MACE (pooled aHR =5.00; 95% CI: 3.30-7.58; P<0.001), with moderate GRADE evidence quality. (II) Continuous variable [per 1 Hounsfield unit (HU) increase]: each 1 HU increase in FAI was associated with a 24% increase in MACE risk (pooled aHR =1.24; 95% CI: 1.08-1.43; P=0.002), with low GRADE evidence quality. Sensitivity analyses and funnel plots indicated robust pooled results and a low likelihood of publication bias. Conclusions: CCTA-derived FAI is a strong independent predictor of MACE. Incorporating FAI into routine CCTA assessment may improve cardiovascular risk stratification, demonstrating significant potential for clinical translation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a meta-analysis in Suspected or confirmed coronary artery disease (CAD) (n=10,288). High pericoronary fat attenuation index (FAI) vs. Low pericoronary fat attenuation index (FAI) was evaluated on Major adverse cardiovascular events (MACE) (aHR 5.00, 95% CI 3.30-7.58, p=<0.001). High pericoronary fat attenuation index (FAI) was significantly associated with an increased risk of major adverse cardiovascular events (pooled aHR 5.00, 95% CI 3.30-7.58) compared to low FAI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: